ADmit Therapeutics SL
About
ADmit Therapeutics has developed the MAP-AD Test, the first prognostic blood test for Alzheimer's disease (AD) dementia. It is based on novel biomarkers discovered by our team and the IVDR has been developed in Barcelona. Using patented mitochondrial DNA biomarkers and AI, it predicts progression to AD in patients with first memory complaints, even before amyloid positivity. This facilitates early personalized interventions, optimizes clinical trial enrollment, and empowers patients and clinicians with crucial foresight. Our solution improves quality of life and offers significant economic savings.
Areas of activity
GENOME RESEARCH
Bioinformatics
LIFE SCIENCE
Diagnostics
E-HEALTH
Health information management
BIOLOGY / BIOTECHNOLOGY
In vitro Testing, Trials
THERAPEUTIC AREA
Neurology
MEDICINE
Neurology, Brain Research
Representatives
CEO
ADmit Therapeutics SL